Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese HSK 1 Your complete learning platform for speakers of 21 languages: Arabic, Bengali, Dutch, English, Farsi, French, German, Hindi, Indonesian, Italian, Japanese, Korean, Portuguese, Russian, Spanish, Tagalog, Thai, Turkish, Ukrainian, Urdu, Vietnamese. By Bernd Sebastian Kamps and Andrea Melis

Breast Cancer

Free Subscription Articles published in Mod Pathol Retrieve available abstracts of 54 articles: HTML format

Single Articles

April 2026
1. DENKERT C, Rachakonda S, Pehl A, Marme F, et al
   Clinical and Molecular Evaluation of HER2-Low and Ultralow Breast Cancer in the PENELOPE-B Clinical Trial Cohort.
   Mod Pathol. 2026 Apr 21:101006. doi: 10.1016/j.modpat.2026.101006.
   PubMed     Abstract available
   
   
   March 2026
2. KRINGS G, Bean GR, Hosfield EM, Rowe JJ, et al
   Genetic Profiling of Mammary Periductal Stromal Tumors With Histologic Correlation Highlights High-Grade and Low-Grade Groups and Similarities to Phyllodes Tumors.
   Mod Pathol. 2026;39:100961.
   PubMed     Abstract available
   
   
   January 2026
3. HU J, Tsang JY, Liu J, Hu H, et al
   Predictors of Response to Neoadjuvant Therapy in HER2-positive Breast Cancer and Pathological Evaluation of HER2 Heterogeneity.
   Mod Pathol. 2026 Jan 29:100935. doi: 10.1016/j.modpat.2025.100935.
   PubMed     Abstract available
   
   
   
4. KWAKKENBOS K, Van Bockstal MR, Shaaban AM, Brogi E, et al
   A Worldwide Survey on Pathological Measurement of Residual Breast Cancer After Neoadjuvant Therapy: Different Interpretations of the ypTNM Classification.
   Mod Pathol. 2026 Jan 22:100963. doi: 10.1016/j.modpat.2026.100963.
   PubMed     Abstract available
   
   
   
5. MCKELVEY B, Torres-Saavedra PA, Li J, Broeckx G, et al
   Agreement Across 10 Artificial Intelligence Models in Assessing Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Breast Cancer Whole-Slide Images.
   Mod Pathol. 2026 Jan 5:100944. doi: 10.1016/j.modpat.2025.100944.
   PubMed     Abstract available
   
   
   
6. RAKHA EA, Quinn CM, Provenzano E, Pinder SE, et al
   Diagnostic Discordance and Error in Breast Pathology: Causes, Classifications, and Medicolegal Implications.
   Mod Pathol. 2026;39:100942.
   PubMed     Abstract available
   
   
   
7. HASHMI AA, Vougiouklakis T, Gazzo A, Wen HY, et al
   Lung Carcinoma Metastatic to the Breast: A Comprehensive Analysis of Clinical Presentation, Morphologic, and Molecular Features, With Emphasis on Diagnostic Pitfalls.
   Mod Pathol. 2026;39:100936.
   PubMed     Abstract available
   
   
   December 2025
8. HUANG X, Varambally S, Anderson SA, Bartow BB, et al
   A Genomic Alteration in GATA3 Affects Treatment Responses With a CDK4/6 Inhibitor Collaborating With p18(INK4C) Expression in Advanced Breast Carcinoma.
   Mod Pathol. 2025;38:100841.
   PubMed     Abstract available
   
   
   November 2025
9. LU X, Luo B, Wei Y, Bu H, et al
   Histologic Categorization of Desmoplastic Reaction in Triple-Negative Breast Cancer: Its Relevance to Neoadjuvant Chemoimmunotherapy Response and Tumor Biology.
   Mod Pathol. 2025 Nov 26:100943. doi: 10.1016/j.modpat.2025.100943.
   PubMed     Abstract available
   
   
   
10. KRINGS G, Shamir ER, Shelley Hwang E, Chen YY, et al
    Genetic Analysis of Early Neoplasia in the Breast: Next-Generation Sequencing of Flat Epithelial Atypia and Associated Ductal and Lobular Lesions.
    Mod Pathol. 2025;38:100820.
    PubMed     Abstract available
    
    
    October 2025
11. RAKHA EA, Tan PH, Van Bockstal MR, Allison KH, et al
    International Expert Consensus Recommendations for HER2 Reporting in Breast Cancer: Focus on HER2-low and Ultralow Categories.
    Mod Pathol. 2025 Oct 28:100925. doi: 10.1016/j.modpat.2025.100925.
    PubMed     Abstract available
    
    
    
12. KHOURY T, Zhan H, Huang X, Ghasemi F, et al
    Predicting the Probability of Residual Axillary Nodal Metastases in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Mod Pathol. 2025 Oct 1:100902. doi: 10.1016/j.modpat.2025.100902.
    PubMed     Abstract available
    
    
    
13. ANH NGUYEN TT, Zhang J, Iqbal J, Ahmed SS, et al
    Proposing New Criteria for Classification of Benign Fibroepithelial Lesions Based on Clinicopathologic Evaluations of 507 Cases with Clinical Outcome.
    Mod Pathol. 2025;38:100812.
    PubMed     Abstract available
    
    
    
14. BADVE S, White JS, Sapunar F, Thoele K, et al
    Analytical Comparison of Commonly Used Laboratory-Developed Tests for the Assessment of Ki-67 in Breast Carcinoma With a Food and Drug Administration-Approved Benchmark.
    Mod Pathol. 2025;38:100813.
    PubMed     Abstract available
    
    
    September 2025
15. MORRAR D, Brogi E, Schwartz CJ, Pareja F, et al
    HER2-ultralow Breast Cancer: Incidence, Clinicopathologic Features and Need for Refined Scoring System.
    Mod Pathol. 2025 Sep 29:100901. doi: 10.1016/j.modpat.2025.100901.
    PubMed     Abstract available
    
    
    
16. FLORIS G, Djerroudi L, Zels G, De Schepper M, et al
    Pitfalls in the Histological Diagnosis of Morphologic Variants of Invasive Lobular Carcinoma of the Breast.
    Mod Pathol. 2025;38:100837.
    PubMed     Abstract available
    
    
    August 2025
17. SCHILDHAUS HU, Badve S, D'Arrigo C, Farshid G, et al
    A Global Ring Study: Concordance Between Ventana PATHWAY anti-HER2/neu (4B5) Companion Diagnostic Assay and Comparators in Detecting HER2-low Breast Cancer.
    Mod Pathol. 2025 Aug 9:100867. doi: 10.1016/j.modpat.2025.100867.
    PubMed     Abstract available
    
    
    
18. HU Y, Jones D, Zhao W, Tozbikian G, et al
    Incidence, Clinicopathologic Features, and Follow-Up Results of human epidermal growth factor receptor-2-Ultralow Breast Carcinoma.
    Mod Pathol. 2025;38:100783.
    PubMed     Abstract available
    
    
    
19. MARKEY M, Kim J, Goldstein Z, Gerardin Y, et al
    Spatial Mapping of Gene Signatures in Hematoxylin and Eosin-Stained Images: A Proof of Concept for Interpretable Predictions Using Additive Multiple Instance Learning.
    Mod Pathol. 2025;38:100772.
    PubMed     Abstract available
    
    
    July 2025
20. STEEN S, Boissin C, Rantalainen M, Acs B, et al
    Histological grade has clinical validity in neoadjuvant treated breast cancer: A multicenter study.
    Mod Pathol. 2025 Jul 25:100850. doi: 10.1016/j.modpat.2025.100850.
    PubMed     Abstract available
    
    
    
21. SU Z, Guo Y, Wesolowski R, Tozbikian G, et al
    Computational Pathology for Accurate Prediction of Breast Cancer Recurrence: Development and Validation of a Deep Learning-based Tool.
    Mod Pathol. 2025 Jul 16:100847. doi: 10.1016/j.modpat.2025.100847.
    PubMed     Abstract available
    
    
    
22. DAI W, Navolotskaia O, Fine JL, Harinath L, et al
    Not All HER2-Positive Breast Cancers Are the Same: Intratumoral Heterogeneity, Low-Level HER2 Amplification, and Their Impact on Neoadjuvant Therapy Response.
    Mod Pathol. 2025;38:100785.
    PubMed     Abstract available
    
    
    
23. RUTLAND CD, Kingsley L, Wang A, Zdravkovic S, et al
    RNA In Situ Hybridization Detection of CRTC1/3::MAML2 Fusions and LINC00473 in Mucoepidermoid Carcinomas and Hidradenomas of Breast, Salivary Glands, and Skin.
    Mod Pathol. 2025;38:100756.
    PubMed     Abstract available
    
    
    May 2025
24. PONS L, Hernandez L, Urbizu A, Arnaldo L, et al
    Molecular Landscape, Genomic Shift and Prediction in the Neoadjuvant Setting of HER2 Positive Breast Cancer.
    Mod Pathol. 2025 May 6:100787. doi: 10.1016/j.modpat.2025.100787.
    PubMed     Abstract available
    
    
    
25. RAKHA EA, Quinn C, Raymond W, Allison KH, et al
    Classification of Fibroepithelial Lesions of the Breast in Core Needle Biopsy With Implications for Further Management.
    Mod Pathol. 2025;38:100734.
    PubMed     Abstract available
    
    
    
26. HAN R, Pareja F, Ross DS, Grabenstetter A, et al
    Frank Invasion in Tall Cell Carcinoma With Reversed Polarity of the Breast: Report of Two Cases.
    Mod Pathol. 2025;38:100714.
    PubMed     Abstract available
    
    
    April 2025
27. JIAO D, Dai H, Fei J, Wang D, et al
    Impact of Hormone Receptor Status and HER2 Expression on Neoadjuvant Targeted Therapy Response in HER2-Positive Breast Cancer: A Multicenter Retrospective Study.
    Mod Pathol. 2025 Apr 15:100778. doi: 10.1016/j.modpat.2025.100778.
    PubMed     Abstract available
    
    
    
28. ABUBAKAR M, Fan S, Klein A, Pfeiffer RM, et al
    Spatially-resolved Single-cell Morphometry of Benign Breast Disease Biopsy Images Uncovers Quantitative Cytomorphometric Features Predictive of Subsequent Invasive Breast Cancer Risk.
    Mod Pathol. 2025 Apr 8:100767. doi: 10.1016/j.modpat.2025.100767.
    PubMed     Abstract available
    
    
    
29. ATALLAH N, Makhlouf S, Li X, Zhang Y, et al
    Prediction of Response to Anti-HER2 Therapy Using A Multigene Assay.
    Mod Pathol. 2025;38:100713.
    PubMed     Abstract available
    
    
    
30. FARSHID G, Armes J, Dessauvagie B, Gilhotra A, et al
    Independent Validation of a HER2-Low Focused Immunohistochemistry Scoring System for Enhanced Pathologist Precision and Consistency.
    Mod Pathol. 2025;38:100693.
    PubMed     Abstract available
    
    
    February 2025
31. CHA YJ, O'Connell CE, Calhoun BC, Felsheim BM, et al
    Genomic Characteristics Related to Histology-based Immune Features in Breast Cancer.
    Mod Pathol. 2025 Feb 14:100736. doi: 10.1016/j.modpat.2025.100736.
    PubMed     Abstract available
    
    
    
32. VAZQUEZ TP, Goncalves R, Gomes da Cunha JP, Silva Rivas FW, et al
    Prognostic Implications of Magee Equation 3 and Residual Cancer Burden in patients receiving Neoadjuvant Chemotherapy for HR-Positive HER2-Negative Breast Cancer.
    Mod Pathol. 2025 Feb 7:100733. doi: 10.1016/j.modpat.2025.100733.
    PubMed     Abstract available
    
    
    January 2025
33. SHENASA E, He Y, Wang Z, Tu D, et al
    Digital Profiling of Immune Biomarkers in Breast Cancer: Relation to Anthracycline Benefit.
    Mod Pathol. 2025 Jan 23:100718. doi: 10.1016/j.modpat.2025.100718.
    PubMed     Abstract available
    
    
    
34. YE Q, Law T, Klippel D, Albarracin C, et al
    Prospective and retrospective analysis of whole slide images of sentinel and targeted lymph node frozen sections in breast cancer.
    Mod Pathol. 2025 Jan 7:100708. doi: 10.1016/j.modpat.2025.100708.
    PubMed     Abstract available
    
    
    
35. LI Z, Hu Y, Jones D, Zhao W, et al
    Clinicopathologic Characteristics and Follow-Up Outcomes of Invasive Breast Carcinoma With Different Positive HER2 Fluorescence In Situ Hybridization Patterns: Experience From a Single Academic Institution.
    Mod Pathol. 2025;38:100637.
    PubMed     Abstract available
    
    
    December 2024
36. KAHILA MMH, Chesebro AL, Giess CS, Rhei E, et al
    Pathologic Features of Malignancies Presenting as Asymmetry on Mammography.
    Mod Pathol. 2024;37:100612.
    PubMed     Abstract available
    
    
    
37. YE J, Theparee T, Bean GR, Rutland CD, et al
    Targeted DNA Sequencing in Diagnosis of Malignant Phyllodes Tumors With Emphasis on Tumors With Keratin and p63 Expression.
    Mod Pathol. 2024;37:100593.
    PubMed     Abstract available
    
    
    November 2024
38. MI H, Varadhan R, Cimino-Mathews AM, Emens LA, et al
    Spatial Architecture of Single-cell and Vasculature in Tumor Microenvironment Predicts Clinical Outcomes in Triple-Negative Breast Cancer.
    Mod Pathol. 2024 Nov 8:100652. doi: 10.1016/j.modpat.2024.100652.
    PubMed     Abstract available
    
    
    
39. PABBA A, Zels G, De Schepper M, Geukens T, et al
    Stromal tumor infiltrating lymphocytes in hormone receptor positive/HER2 negative metastatic breast cancer.
    Mod Pathol. 2024 Nov 8:100650. doi: 10.1016/j.modpat.2024.100650.
    PubMed     Abstract available
    
    
    October 2024
40. DJERROUDI L, Bendali A, Fuhrmann L, Benoist C, et al
    E-Cadherin Mutational Landscape and Outcomes in Breast Invasive Lobular Carcinoma.
    Mod Pathol. 2024;37:100570.
    PubMed     Abstract available
    
    
    August 2024
41. GHANNAM SF, Makhlouf S, Alsaleem M, Rutland CS, et al
    The conflicting prognostic role of the stroma-ratio in breast cancer molecular subtypes.
    Mod Pathol. 2024 Aug 29:100607. doi: 10.1016/j.modpat.2024.100607.
    PubMed     Abstract available
    
    
    
42. SCHWARTZ CJ, Marra A, Selenica P, Gazzo A, et al
    RB1 Genetic Alterations in Estrogen Receptor-Positive Breast Carcinomas: Correlation With Neuroendocrine Differentiation.
    Mod Pathol. 2024;37:100541.
    PubMed     Abstract available
    
    
    July 2024
43. RAMMAL R, Goel K, Motanagh SA, Carter GJ, et al
    Immunohistochemical Profile of Triple-Negative Breast Cancers: SOX10 and AR Dual Negative Tumors Have Worse Outcomes.
    Mod Pathol. 2024;37:100517.
    PubMed     Abstract available
    
    
    June 2024
44. FARSHID G, Armes J, Dessauvagie B, Gilhotra A, et al
    Development and Validation of a HER2-Low Focused IHC Scoring System with High Inter-Observer Concordance The Australian HER2-low Breast Cancer Concordance Study.
    Mod Pathol. 2024 Jun 7:100535. doi: 10.1016/j.modpat.2024.100535.
    PubMed     Abstract available
    
    
    May 2024
45. INGEBRIKTSEN LM, Svanoe AA, Saele AKM, Humlevik ROC, et al
    Age-related clusters and favorable immune phenotypes in breast cancer of the young.
    Mod Pathol. 2024 May 27:100529. doi: 10.1016/j.modpat.2024.100529.
    PubMed     Abstract available
    
    
    
46. AJABNOOR R, Zhang G, Hu Y, Gao Y, et al
    Breast Cancer with HER2 IHC 2+ and Average HER2 Signals/Cell >/= 6 and HER2/CEP17 Ratio < 2: A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype.
    Mod Pathol. 2024 May 27:100530. doi: 10.1016/j.modpat.2024.100530.
    PubMed     Abstract available
    
    
    
47. DJERROUDI L, El Sabeh-Ayoun A, Benoist C, Pierron G, et al
    Molecular and Clinical Portrait of HER2-low Invasive Lobular Carcinomas.
    Mod Pathol. 2024;37:100463.
    PubMed     Abstract available
    
    
    April 2024
48. DE SCHEPPER M, Koorman T, Richard F, Christgen M, et al
    Integration of pathological criteria and immunohistochemical evaluation for invasive lobular carcinoma diagnosis: recommendations from the European Lobular Breast Cancer Consortium.
    Mod Pathol. 2024 Apr 17:100497. doi: 10.1016/j.modpat.2024.100497.
    PubMed     Abstract available
    
    
    
49. HARINATH L, Villatoro TM, Clark BZ, Fine JL, et al
    Upgrade Rates of Variant Lobular Carcinoma In Situ Compared to Classic Lobular Carcinoma In Situ Diagnosed in Core Needle Biopsies: A 10-Year Single Institution Retrospective Study.
    Mod Pathol. 2024;37:100462.
    PubMed     Abstract available
    
    
    February 2024
50. SHAFIQUE A, Gonzalez R, Pantanowitz L, Tan PH, et al
    A Preliminary Investigation into Search and Matching for Tumor Discrimination in World Health Organization Breast Taxonomy Using Deep Networks.
    Mod Pathol. 2024;37:100381.
    PubMed     Abstract available
    
    
    
51. DERAKHSHAN F, Da Cruz Paula A, Selenica P, da Silva EM, et al
    Nonlobular Invasive Breast Carcinomas with Biallelic Pathogenic CDH1 Somatic Alterations: A Histologic, Immunophenotypic, and Genomic Characterization.
    Mod Pathol. 2024;37:100375.
    PubMed     Abstract available
    
    
    October 2023
52. MAKHLOUF S, Althobiti M, Toss M, Muftah AA, et al
    The Clinical and Biological Significance of Estrogen Receptor-Low Positive Breast Cancer.
    Mod Pathol. 2023;36:100284.
    PubMed     Abstract available
    
    
    
53. BLACK MA, Neumann NM, Krings G, Najjar S, et al
    Genetic and Immunohistochemical Profiling of Mammary Hidradenoma and Comparison to Mucoepidermoid Carcinoma.
    Mod Pathol. 2023;36:100270.
    PubMed     Abstract available
    
    
    
54. ATALLAH NM, Wahab N, Toss MS, Makhlouf S, et al
    Deciphering the Morphology of Tumor-Stromal Features in Invasive Breast Cancer Using Artificial Intelligence.
    Mod Pathol. 2023;36:100254.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum